Co-Authors
This is a "connection" page, showing publications co-authored by Frank van de Veerdonk and Roger Brüggemann.
Connection Strength
2.547
-
Outcomes Associated With Use of a Kinin B2 Receptor Antagonist Among Patients With COVID-19. JAMA Netw Open. 2020 08 03; 3(8):e2017708.
Score: 0.896
-
The Challenge of Managing COVID-19 Associated Pulmonary Aspergillosis. Clin Infect Dis. 2021 12 06; 73(11):e3615-e3616.
Score: 0.246
-
COVID-19-associated Aspergillus tracheobronchitis: the interplay between viral tropism, host defence, and fungal invasion. Lancet Respir Med. 2021 07; 9(7):795-802.
Score: 0.237
-
Dysregulated Innate and Adaptive Immune Responses Discriminate Disease Severity in COVID-19. J Infect Dis. 2021 04 23; 223(8):1322-1333.
Score: 0.235
-
Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion. Intensive Care Med. 2020 Aug; 46(8):1524-1535.
Score: 0.222
-
Kallikrein-kinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome. Elife. 2020 04 27; 9.
Score: 0.220
-
Moderate correlation between systemic IL-6 responses and CRP with trough concentrations of voriconazole. Br J Clin Pharmacol. 2018 09; 84(9):1980-1988.
Score: 0.193
-
Itraconazole or Amphotericin B for Talaromycosis. N Engl J Med. 2017 10 05; 377(14):1402-1403.
Score: 0.184
-
Taskforce report on the diagnosis and clinical management of COVID-19 associated pulmonary aspergillosis. Intensive Care Med. 2021 08; 47(8):819-834.
Score: 0.060
-
Diagnosing COVID-19-associated pulmonary aspergillosis. Lancet Microbe. 2020 Jun; 1(2):e53-e55.
Score: 0.055